Treatment of Tuberculous Pleurisy With Contezolid in a Child With Glucose-6-Phosphate Dehydrogenase Deficiency: The First Case Report.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
ppublish
Résumé
This is the first reported case of a pediatric patient with tuberculous pleurisy and glucose-6-phosphate dehydrogenase deficiency treated with contezolid concomitantly with other antituberculous drugs. The patient responded well to treatment, and no adverse events were observed. These findings suggest that contezolid may be a potential therapeutic option for tuberculous pleurisy in children and adolescents with glucose-6-phosphate dehydrogenase deficiency.
Identifiants
pubmed: 39163300
doi: 10.1097/INF.0000000000004369
pii: 00006454-202409000-00010
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
869-871Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
WHO Consolidated Guidelines on Drug-resistant Tuberculosis Treatment. WHO Guidelines Approved by the Guidelines Review Committee; 2019.
Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant mycobacterium tuberculosis in China. Front Med (Lausanne). 2022;9:1067516.
Martinez L, Cords O, Horsburgh CR, et al.; Pediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395:973–984.
Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 2018;378:60–71.
WHO Consolidated Guidelines on Tuberculosis: Module 5: Management of Tuberculosis in Children and Adolescents. WHO Guidelines Approved by the Guidelines Review Committee; 2022.
McCurdy PR, Donohoe RF. Pyridoxine-responsive anemia conditioned by isonicotinic acid hydrazide. Blood. 1966;27:352–362.
Hoy SM. Contezolid: first approval. Drugs. 2021;81:1587–1591.
Li B, Liu Y, Luo J, et al. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment. Front Pharmacol. 2023;14:1157437.
Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57:4487–4497.
Wang J, Nie W, Ma L, et al. Clinical utility of contezolid-containing regimens in 25 cases of linezolid-intolerable tuberculosis patients. Infect Drug Resist. 2023;16:6237–6245.